News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MarketBeat Deals and strategy
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
RTW Investments, LP and its managing partner, Roderick Wong, M.D., have reported a beneficial ownership of 4,251,996 shares of Spyre Therapeutics (SYRE) common stock, representing 4.8% of the outstanding shares. These shares are held by RTW-managed funds, with RTW Investments and Dr. Wong exercising …
Dimensional Fund Advisors LP has reduced its stake in Spyre Therapeutics (NASDAQ:SYRE) by 38.3%, selling 29,593 shares but retaining 47,697 shares valued at $2.4 million. Despite this, analysts maintain a "Moderate Buy" rating with an average price target of $111.69, while institutional investors collectively …
Analysts have raised the average 12-month price target for Spyre Therapeutics, Inc. (SYRE) stock to $126.85, up from $124.71, with individual forecasts ranging from $115 to $140. This new target suggests a potential upside of approximately 22% from its August 12 closing price. The …
This article provides financial information for Spyre Therapeutics, Inc. (SWB:3920) on the Stuttgart Stock Exchange, specifically focusing on its price-to-book forward ratio. It also highlights the various products, community features, and business solutions offered by TradingView, the platform hosting this financial data.
BTIG Research has increased its price target for Spyre Therapeutics (NASDAQ:SYRE) to $132 from $112, maintaining a "Buy" rating and suggesting a 25.32% upside. This positive outlook follows Spyre Therapeutics beating quarterly earnings expectations, though insiders have sold a significant amount of stock recently. …
BTIG analyst Julian Harrison has maintained a 'Buy' rating for Spyre Therapeutics (SYRE) and raised its price target to $132.00 from $112.00. While analysts show growing confidence in SYRE's potential, the company has a low GF Score™ of 26/100, indicating weaknesses in profitability and …
An insider at Spyre Therapeutics (SYRE) has reportedly sold shares valued at $2,404,190, according to a recent SEC filing. This transaction follows other insider sales and occurs as the company launches a new program and a mid-stage trial for a drug combination to treat …
Bank of America Corp DE significantly increased its stake in Spyre Therapeutics (NASDAQ:SYRE) by 192.6% in the first quarter, now holding 1.23 million shares valued at approximately $61.9 million. Institutional investors collectively own 80.39% of the company, and analysts maintain a "Moderate Buy" rating …
Spyre Therapeutics (NASDAQ:SYRE) Director Jeffrey Albers sold 18,000 shares of the company's stock for $1,881,900, reducing his holdings by 65.79%. The transaction occurred as Spyre shares traded near record highs and the company reported strong quarterly earnings, beating analyst expectations. Despite the insider sale, …
Jeffrey W. Albers, a director at Spyre Therapeutics (SYRE), exercised stock options for 5,000 shares and sold a total of 23,000 shares on August 7, 2026. The sales, which included indirect ownership through Sessions LLC, were executed at weighted average prices slightly above $104 …
Jeffrey W. Albers, a director at Spyre Therapeutics (NASDAQ:SYRE), sold 23,000 shares of common stock totaling approximately $2.4 million on August 7, 2026, under a Rule 10b5-1 trading plan. The sales occurred while the stock was near its 52-week high, with InvestingPro analysis indicating …
Spyre Therapeutics has initiated a Phase 2 trial, SKYLIGHT, for SPY772, a combination therapy targeting hidradenitis suppurativa (HS). The trial will evaluate the dual inhibition of TL1A and IL-17A/F using SPY072 and bimekizumab, with topline data expected in late 2027 or early 2028. This …
Spyre Therapeutics has announced the launch of its SPY772 program, a combination therapy involving long-acting anti-TL1A and anti-IL-17A/F antibodies, and the initiation of the Phase 2 SKYLIGHT trial for Hidradenitis Suppurativa (HS). The SKYLIGHT trial will evaluate the dual inhibition of TL1A and IL-17A/F …
Spyre Therapeutics has shown exceptional returns over the past three years, with its stock returning roughly 7x, but current valuations suggest it is expensive. The company recently announced positive Phase 2 data for its ulcerative colitis programs, which could support higher growth expectations. However, …
This article displays the "Price to sales forward" metric for Spyre Therapeutics, Inc. (NASDAQ: SYRE) on TradingView. It appears to be a financial data page rather than a detailed analytical article, offering a single data point within the financial overview of the company.
This article reports on Spyre Therapeutics, Inc.'s SEC Form 144 filing from August 7, 2026. The filing details a proposed sale of 18,000 shares of common stock by an individual, acquired through an open market purchase in June 2022, with an aggregate market value …
WALTHAM, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment …
Search by ticker symbol or company name and select a result to open its chart.